{"nctId":"NCT00473434","briefTitle":"An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia","startDateStruct":{"date":"2007-04"},"conditions":["Schizophrenia"],"count":64,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone"]}],"interventions":[{"name":"Paliperidone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must satisfy the following criteria to be eligible for this study: patients with diagnoses of schizophrenia according to the DSM-IV criteria including newly diagnosed patients\n* Out-patients or in-patients with expected discharge within 8 weeks\n* Patients or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from participating in the study: patients who are resistant to antipsychotic treatment\n* Patients who have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months\n* Patients with CGl-S scores \\> 6 or who who have been hospitalized for longer than 8 continuous weeks during the past 6 months\n* Pregnant or breast-feeding females\n* Patients with a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"2.3"}]}]}]},{"type":"PRIMARY","title":"The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"2.4"}]}]}]},{"type":"PRIMARY","title":"The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"The Mean Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"1.8"}]}]}]},{"type":"PRIMARY","title":"The Median Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Clinical Global Impression of Severity (CGI-S) Throughout the Study","description":"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill patients\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.2"},{"groupId":"OG001","value":"3.3","spread":"1.1"},{"groupId":"OG002","value":"3.2","spread":"1.0"},{"groupId":"OG003","value":"3.1","spread":"1.1"},{"groupId":"OG004","value":"2.8","spread":"1.0"},{"groupId":"OG005","value":"2.8","spread":"1.0"},{"groupId":"OG006","value":"2.9","spread":"1.1"},{"groupId":"OG007","value":"2.7","spread":"1.1"},{"groupId":"OG008","value":"2.7","spread":"0.8"},{"groupId":"OG009","value":"2.9","spread":"1.2"},{"groupId":"OG010","value":"2.7","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"The Global Assessment of Functioning (GAF) Throughout the Study","description":"The GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":"14.7"},{"groupId":"OG001","value":"58.9","spread":"15.0"},{"groupId":"OG002","value":"63.9","spread":"15.3"},{"groupId":"OG003","value":"63.9","spread":"15.6"},{"groupId":"OG004","value":"66.3","spread":"13.8"},{"groupId":"OG005","value":"65.4","spread":"14.6"},{"groupId":"OG006","value":"65.1","spread":"14.7"},{"groupId":"OG007","value":"71.1","spread":"13.3"},{"groupId":"OG008","value":"71.6","spread":"14.9"},{"groupId":"OG009","value":"69.0","spread":"17.2"},{"groupId":"OG010","value":"63.3","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Presenting Clinical Deterioration Throughout the Study","description":"This Outcome Measure is intended to document only the hospitalizations associated with clinical deterioration, ie, when the patient needs to be hospitalized due to exacerbation of psychotic symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"14.7"},{"groupId":"OG001","value":"5.3","spread":"15.0"},{"groupId":"OG002","value":"13.5","spread":"15.3"},{"groupId":"OG003","value":"5.9","spread":"15.6"},{"groupId":"OG004","value":"7.1","spread":"13.8"},{"groupId":"OG005","value":"3.2","spread":"14.6"},{"groupId":"OG006","value":"3.7","spread":"14.7"},{"groupId":"OG007","value":"0","spread":"13.3"},{"groupId":"OG008","value":"0","spread":"14.9"},{"groupId":"OG009","value":"0","spread":"17.2"},{"groupId":"OG010","value":"12.5","spread":"15.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5.4","spread":null},{"groupId":"OG003","value":"2.9","spread":null},{"groupId":"OG004","value":"3.6","spread":null},{"groupId":"OG005","value":"3.2","spread":null},{"groupId":"OG006","value":"7.4","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"5.9","spread":null},{"groupId":"OG010","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"8.1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3.2","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Hospitalizations Throughout the Study","description":"This outcome measure is intended to document all hospitalizations that occurred throughout the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":"14.7"},{"groupId":"OG001","value":"2","spread":"15.0"},{"groupId":"OG002","value":"6","spread":"15.3"},{"groupId":"OG003","value":"2","spread":"15.6"},{"groupId":"OG004","value":"3","spread":"13.8"},{"groupId":"OG005","value":"1","spread":"14.6"},{"groupId":"OG006","value":"1","spread":"14.7"},{"groupId":"OG007","value":"0","spread":"13.3"},{"groupId":"OG008","value":"0","spread":"14.9"},{"groupId":"OG009","value":"1","spread":"17.2"},{"groupId":"OG010","value":"2","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"The Length of Hospitalizations Throughout the Study","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"11.5"},{"groupId":"OG001","value":"66","spread":"0"},{"groupId":"OG002","value":"7.3","spread":"6.0"},{"groupId":"OG003","value":"28.0","spread":"5.7"},{"groupId":"OG004","value":"179.0","spread":"220.6"},{"groupId":"OG005","value":"34","spread":"0"},{"groupId":"OG006","value":"19","spread":"0"},{"groupId":"OG007","value":"4","spread":"0"},{"groupId":"OG008","value":"20.5","spread":"10.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":64},"commonTop":["Insomnia","Headache","Nausea","Tremor","Akathisia"]}}}